Erectile Dysfunction Drugs Market Size Is Estimated To Reach $3.2 Billion By 2022: Grand View Research, Inc.
The
global erectile dysfunction drugs market is expected to
reach USD 3.2 billion by 2022 according to a new report by Grand View Research Inc.
Rising adoption of sedentary lifestyle and increasing prevalence of conditions
causing erectile dysfunction such as stress, hypertension, and related
medications are the key factors expected to widen the target population base
for this market.
However,
the market is estimated to witness decline in revenue over the forecast period.
Expiration of key drugs from 2017 to 2019 is likely to curb revenue growth. On
the other hand, the market is likely to open up new avenues for the generic
manufacturers to capitalize on. The increasing risk of sexually transmitted
diseases, narrowing of insurance coverage for erectile dysfunction treatment,
growing threat from counterfeit drugs, and presence of social stigma in
developing countries are some factors limiting penetration rates.
North
America erectile dysfunction drugs market, by product, 2012 - 2022, (USD
Million)
Browse full
research report on Erectile Dysfunction Drugs Market: http://www.grandviewresearch.com/industry-analysis/erectile-dysfunction-drugs-market
Further
key findings from the report suggest:
- Viagra accounted for over 47.0% of the total
revenue in 2014. It is generally considered as the first line of treatment
for erectile dysfunction. Brand loyalty and advantages associated with
this drug such as high efficacy, and effectiveness are the major factors
attributing for its large market share.
- Cialis (tadalafil) from Eli Lilly & Co. and
Levitra (vardenafil) from Bayer AG are known to be the competitors for
Viagra globally. Cialis (tadalafil) was approved in 2003 by the U.S. FDA,
as a prescription drug in the U.S. Cialis is also known as “The Weekend
Pill” owing to its 36-hour effectiveness.
- After the patent expiration of key drugs such
as Cialis (tadalafil) in 2017 and Levitra (vardenafil) in 2018, other
drugs such as Stendra/Spedra, Zydena (udenafil), and Vitaros (Alprostadil
Cream) are expected to capture the market share during the forecasts
period.
- North America constituted the largest share of
approximately 55.0% in 2013 of the total erectile dysfunction market.
Extension of patent exclusivity rights for Viagra (sildenafil citrate) in
the U.S. till 2019 along with introduction of new erectile dysfunction
drugs such as Zydena (udenafil) and Stendra/Spedra (avanafil) will be the
major factors responsible for market growth during the forecasts period.
- Asia Pacific accounted for a revenue share of
over 16.5% in 2012 owing to the presence of a lucrative market for generic
drugs, untapped opportunities, and increasing awareness related to
erectile dysfunction in this region
- Apricus Biosciences Inc., Cristalia Produtos
Quimicos Farmaceuticos Ltd., Bayer AG, Dong-A Pharmaceutical Co. Ltd.,
Meda Pharmaceuticals, Inc., Eli Lilly and Company, Pfizer, Inc., S.K.
Chemicals Co. Ltd., and Vivus, Inc. are some major players of this market
- Extensive R&D carried out by companies and
high unmet needs in developing economies are expected to boost industrial
growth. Key manufacturers are targeting regions with unmet clinical needs
by entering into agreement with local manufacturers and distributors. Key
players are constantly engaged in developing novel drugs in an attempt to
improve the presence and ensure sustainability.
Browse more
reports of this category by Grand View Research: http://www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has segmented the global erectile dysfunction drugs
market on the basis of product and region:
Erectile
Dysfunction Drugs Product Outlook (Revenue, USD Million, 2012 – 2022)
- Viagra
(sildenafil citrate)
- Cialis
(tadalafil)
- Levitra/Staxyn
(vardenafil)
- Stendra/Spedra
(avanafil)
- Zydena
(udenafil)
- Vitaros
(Alprostadil Cream)
- Others
Erectile
Dysfunction Drugs Regional Outlook (Revenue, USD Million, 2012 – 2022)
- North
America
- Europe
- Asia
Pacific
- RoW
Access
Press Release By Grand View Research: http://www.grandviewresearch.com/press-release/global-erectile-dysfunction-drugs-market
About Grand
View Research:
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco.
The company provides syndicated research reports, customized research
reports, and consulting services. To help clients make informed business
decisions, we offer market intelligence studies ensuring relevant and
fact-based research across a range of industries, from technology to chemicals,
materials and healthcare.
Comments
Post a Comment